Evidence map›Paper›PMID 39209859›Full record

ArticleNature communications2024

Bacterial cell surface characterization by phage display coupled to high-throughput sequencing.

Casey N Grun, Ruchi Jain, Maren Schniederberend, Charles B Shoemaker, Bryce Nelson, Barbara I Kazmierczak

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Casey N GrunDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-4563-6358
Ruchi JainDepartment of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA.
Maren SchniederberendDepartment of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA.ORCID 0000-0002-5904-0280
Charles B ShoemakerDepartment of Infectious Disease and Global Health, Tufts Cummings School of Veterinary Medicine, North Grafton, MA, USA.ORCID 0000-0001-9738-1361
Bryce NelsonDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT, USA.
Barbara I KazmierczakDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT, USA. barbara.kazmierczak@yale.edu.ORCID 0000-0002-8162-803X

Funding

High Performance Computing Instrumentation for the Yale Center for Genome AnalysisS10OD030363 · OD · YALE UNIVERSITY · PI MANE, SHRIKANT M · 2022 to 2022
$1.2M
NIH HHS S10 OD030363
6 · The paper itself

Abstract

The remarkable capacity of bacteria to adapt in response to selective pressures drives antimicrobial resistance. Pseudomonas aeruginosa illustrates this point, establishing chronic infections during which it evolves to survive antimicrobials and evade host defenses. Many adaptive changes occur on the P. aeruginosa cell surface but methods to identify these are limited. Here we combine phage display with high-throughput DNA sequencing to create a high throughput, multiplexed technology for surveying bacterial cell surfaces, Phage-seq. By applying phage display panning to hundreds of bacterial genotypes and analyzing the dynamics of the phage display selection process, we capture important biological information about cell surfaces. This approach also yields camelid single-domain antibodies that recognize key P. aeruginosa virulence factors on live cells. These antibodies have numerous potential applications in diagnostics and therapeutics. We propose that Phage-seq establishes a powerful paradigm for studying the bacterial cell surface by identifying and profiling many surface features in parallel.

Indexed as

Cell Surface Display TechniquesHigh-Throughput Nucleotide SequencingPseudomonas aeruginosaCell MembranePeptide LibrarySingle-Domain AntibodiesVirulence FactorsPeptide LibrarySingle-Domain AntibodiesVirulence Factors

Identifiers

PMID39209859
PMCPMC11362561

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.